Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy
A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She was treated for short-gut syn...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/107479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849694977281490944 |
|---|---|
| author | Laura E. Zyczynski Jonathan B. McHugh Thomas E. Gribbin Scott M. Schuetze |
| author_facet | Laura E. Zyczynski Jonathan B. McHugh Thomas E. Gribbin Scott M. Schuetze |
| author_sort | Laura E. Zyczynski |
| collection | DOAJ |
| description | A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She was treated for short-gut syndrome with teduglutide, a glucagon-like peptide-2 (GLP-2) analog, which led to reduction of TPN requirements. However, a few months later, she developed metastatic alveolar rhabdomyosarcoma. Though a causative relationship is unlikely between the peptide and ARMS due to the brief time course between teduglutide therapy and sarcoma diagnosis, neoplastic growth may have been accelerated by the GLP-2 analog, causing release of IGF-1. The transmembrane receptor for IGF-1 is frequently overexpressed in ARMS and is implicated in cell proliferation and metastatic behavior. This case describes a rare incidence of metastatic alveolar rhabdomyosarcoma in a sexagenarian and possibly the first case reported associated with the use of teduglutide. Teduglutide was discontinued due to a potential theoretical risk of acceleration of sarcoma growth, and the patient’s rhabdomyosarcoma is in remission following sarcoma chemotherapy. |
| format | Article |
| id | doaj-art-96daaea9026e433d92ecd7953e77a511 |
| institution | DOAJ |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-96daaea9026e433d92ecd7953e77a5112025-08-20T03:19:53ZengWileyCase Reports in Oncological Medicine2090-67062090-67142015-01-01201510.1155/2015/107479107479Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 TherapyLaura E. Zyczynski0Jonathan B. McHugh1Thomas E. Gribbin2Scott M. Schuetze3Department of Internal Medicine, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USADepartment of Pathology, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USAMercy Health Lacks Cancer Center, 250 Cherry Street SE, Grand Rapids, MI 489503, USADepartment of Internal Medicine, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USAA 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She was treated for short-gut syndrome with teduglutide, a glucagon-like peptide-2 (GLP-2) analog, which led to reduction of TPN requirements. However, a few months later, she developed metastatic alveolar rhabdomyosarcoma. Though a causative relationship is unlikely between the peptide and ARMS due to the brief time course between teduglutide therapy and sarcoma diagnosis, neoplastic growth may have been accelerated by the GLP-2 analog, causing release of IGF-1. The transmembrane receptor for IGF-1 is frequently overexpressed in ARMS and is implicated in cell proliferation and metastatic behavior. This case describes a rare incidence of metastatic alveolar rhabdomyosarcoma in a sexagenarian and possibly the first case reported associated with the use of teduglutide. Teduglutide was discontinued due to a potential theoretical risk of acceleration of sarcoma growth, and the patient’s rhabdomyosarcoma is in remission following sarcoma chemotherapy.http://dx.doi.org/10.1155/2015/107479 |
| spellingShingle | Laura E. Zyczynski Jonathan B. McHugh Thomas E. Gribbin Scott M. Schuetze Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy Case Reports in Oncological Medicine |
| title | Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy |
| title_full | Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy |
| title_fullStr | Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy |
| title_full_unstemmed | Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy |
| title_short | Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy |
| title_sort | alveolar rhabdomyosarcoma in a 69 year old woman receiving glucagon like peptide 2 therapy |
| url | http://dx.doi.org/10.1155/2015/107479 |
| work_keys_str_mv | AT lauraezyczynski alveolarrhabdomyosarcomaina69yearoldwomanreceivingglucagonlikepeptide2therapy AT jonathanbmchugh alveolarrhabdomyosarcomaina69yearoldwomanreceivingglucagonlikepeptide2therapy AT thomasegribbin alveolarrhabdomyosarcomaina69yearoldwomanreceivingglucagonlikepeptide2therapy AT scottmschuetze alveolarrhabdomyosarcomaina69yearoldwomanreceivingglucagonlikepeptide2therapy |